

## Ghada M. Kunter, MD

---

Ghada M. Kunter, FRCP, received her medical degree from the University of Mosul College of Medicine in Mosul, Iraq. With vast experience treating various types of cancers, Dr. Kunter is board certified in internal medicine, medical oncology.

Her academic background includes serving as a Clinical Fellow with the Winship Cancer Institute at Emory University's Winship Cancer Institute and with the H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida. She also has been named Fellow with the Royal College of Physicians of Edinburgh.

Dr. Kunter provides patient-centered cancer care at NGOC's **Jasper Cancer Center**.

<b>Personal Data</b>	Birthplace: Mosul, Iraq
<b>Medical Education</b>	Doctor of Medicine University of Mosul College of Medicine Mosul, Iraq June 1988
<b>Postdoctoral Training</b>	<p><b>RESIDENCY</b> OB/GYN University of Mosul College of Medicine Mosul, Iraq July 1991 – June 1993</p> <p>Internal Medicine/Pediatric University of Kansas, School of Medicine Wichita, Kansas July 2000 – June 2004</p> <p><b>FELLOWSHIP</b> Clinical Fellow, Pediatric Hematology/Oncology Washington University, School of Medicine Children's Hospital in St. Louis St. Louis, Missouri July 2004 – June 2007</p> <p>Postdoctoral Research Fellow, Adult Hematology Washington University, School of Medicine Children's Hospital in St. Louis St. Louis, Missouri July 2007 – June 2008</p> <p>Instructor, Division of Hematology/Oncology Washington University, School of Medicine St. Louis, Missouri July 2008 - June 2011</p> <p>Clinical Fellow, Blood &amp; Marrow Transplantation H. Lee Moffitt Cancer Center and Research Institute University of South Florida Tampa, Florida July 2011 – December 2012</p>

	<p>Clinical Fellow, Adult Oncology Winship Cancer Institute, Emory University, School of Medicine Atlanta, Georgia July 2013 – June 2015</p>
<b>Board Certification</b>	<p>American Board of Internal Medicine, Medical Oncology, 2015 American Board of Internal Medicine, Pediatric Hematology/Oncology, 2013 American Board of Internal Medicine, Pediatrics, 2011 American Board of Internal Medicine, Internal Medicine, 2004</p>
<b>Medical Licensure</b>	<p>State of Georgia, 2017</p>
<b>Major Research Interests</b>	<p>Clinical Trials (Oncology &amp; Hematology)</p>
<b>Awards &amp; Honors</b>	<p>Winship 5K Delta myeloma scholar starting, 10/2014 - 07/2015 American Society of Hematology, abstract achieving award, 12/2012 American Society of Hematology, abstract achieving award, 12/2011 American Society of Hematology, abstract achieving award, 12/2007 Postdoctoral Fellowship, Hope Street Kids Grant and Fellowship Awards Recipient, 07/2007 - 07/2009 Postdoctoral Fellowship, American Society of Clinical Oncology, Young Investigator Award, 07/2007 - 07/2008 American Society of Hematology, abstract achieving award, 12/2006 Third Place award recipient, Annual Kansas Chapter ACP-ASIM associate competition, statistically showing that the "Measured Census" Does Not Accurately Reflect the Actual Workload, Sept 2002 United Nations, Multi-National Medical Award for medical effort and dedication during the Gulf War, 03/1991-08/1991</p>
<b>Publications</b>	<p>Hossain MS1, Kunter GM2, El-Najjar VF3, Jaye DL3, Al-Kadhimi Z1, Taofeek OK1, Li JM1, Waller EK1. PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in all-HSCT recipients.</p> <p>Kunter G, Perkins J, Pidala J, Nishihori T, Fernandez H, Field T, Perez L, Locke F, Ayala E, Anasetti C. Pharmacokinetic ally-targeted BU and fludarabine as conditioning before allogenic hematopoietic cell transplantation for adults with ALL in first remission. Bone Marrow Transplantation, (2 Sept 2013) doi: 10.1038/bmt.2013.121.</p> <p>Kunter G, Woloszynek JR, Link DC. A truncation mutant of Csf3r cooperates with PML-RARa to induce acute myeloid leukemia in mice. Exp Hematol. 10 Sept 2011.</p> <p>Liu F*, Kunter G*, Krem M*, Eades W, Cain J, Tomasson M, Henninghausen L, Link DC. G-CSF receptor mutations found in patients with severe congenital neutropenia induce hematopoietic stem self-renewal that is mediated by STATS, JCI, 118:946-55, 2008.</p> <p>Link DC, Kunter G, Kasai Y, Zhao Y, Miner T, McLellan MD, Ries RE, Kapur D, Nagarajan R, Dale DC, Bolyard AA, Boxer LA, Welte K, Zeidler C, Donadieu J, Bellane-Chantelot C, Vardiman JW, Caligiuri MA, Bloomfield CD, DiPersio JF, Tomasson MH, Graubert TA, Westervelt P, Watson M, Shannon W, Baty J, Mardis ER, Wilson RK, Ley TJ. Distinct patterns of mutations in de novo AML arising in the setting of severe congenital neutropenia. Blood, 110:1648-1655,</p>

	<p>2007.</p> <p>Mackie GC, Shulkin BL, Ribeiro RC, Worden FP, Gauger PG, Mody RJ, Connolly LP, Kunter G, Rodriguez-Galindo C, Wallis JW, Hurwitz CA, Scheingart DE. J Clin Endocrinol Metab. 2006 Jul; 91(7):2665-2671. Use of [18F] fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma.</p>
<b>Regional, National Contributions</b>	<p>Poster: 2012 BMT Tandem Meetings Title: Survival Advantage of the Addition of Cell Therapy to Chemotherapy in Adult Patients with Relapsed AML after Allogeneic Hematopoietic Stem Cell Transplantation.</p> <p>Poster: American Society of Hematology 2012 Title: Survival advantage of cell therapy over cytotoxic therapy alone in adult patients with relapsed AML after Allogeneic Hematopoietic Stem Cell Transplantation.</p> <p>Poster: 2nd International Workshop on the Biology, Prevention and Treatment of Relapse after Hematopoietic Stem Cell Transplantation Meeting on November 5-6, 2012 at NIH Bethesda, MD Title: Survival advantage of cell therapy over cytotoxic therapy alone in adult patients with relapsed AML after Allogeneic Hematopoietic Stem Cell Transplantation.</p> <p>Oral Presentation: American Society of Hematology 2011 Title: Fludarabine and Targeted Busulfan is Safe and Effective Conditioning Before Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia in First Remission.</p> <p>Oral Presentation: American Society of Hematology 2010 Title: Alterations in the bone marrow microenvironment contribute to oxidative stress and DNA damage in hematopoietic stem/progenitors carrying a Csf3r truncation mutation.</p> <p>Poster: American Society of Pediatric Hematology/Oncology 2009 Title: Molecular Mechanisms of Myelodysplastic Syndrome in Severe Congenital Neutropenia</p> <p>Poster: American Society of Hematology 2009 Title: Increased ROS stress and alterations in the bone marrow microenvironment contribute to DNA damage in hematopoietic stem/progenitors carrying a Csf3r truncation mutation.</p> <p>Poster: American Society of Hematology 2007 Title: G-CSFSR Mutations Present in Patients with Severe Congenital Neutropenia Cooperate with PML-RAR* to Induce Acute Myeloid Leukemia in Mice.</p> <p>Oral Presentation: American Society of Hematology 2006 Title: G-CSF Receptor Mutations found in patients with Severe Congenital Neutropenia confer a strong competitive growth advantage at the Hematopoietic Stem Cell Level that is mediated by STAT5 activation.</p>